BACKGROUND: Acinar cell carcinoma (ACC) of the pancreas is a rare neoplasm, accounting for 1% of all pancreatic neoplasms. There remains a lack of data regarding the use of systemic therapy in this disease. We present a series of 40 consecutive cases of ACC of the pancreas treated at Memorial Sloan-Kettering Cancer Center, with an emphasis on evaluation of activity of new therapeutic agents. METHODS: Patients reviewed at our institution from January 2000 through January 2011 were identified from an institutional database with prior institutional review board approval. Pathology was confirmed in all cases as ACC or a closely related entity. RESULTS: Forty patients were identified; 29 were male (73%). The median age at diagnosis was 65 years (range, 16-87 years). The median overall survival (OS) time for patients with localized, resectable disease was 56.9 months and the OS time for patients with metastatic ACC (n = 18) was 19.6 months. Six patients with metastatic or recurrent ACC had a partial response to chemotherapy and five patients had stable disease for ≥6 months on systemic chemotherapy. Clinical observation was made of a patient with ACC and hereditary nonpolyposis colorectal cancer and a patient with ACC and a BRCA1 germline mutation. CONCLUSIONS: ACC is moderately chemoresponsive to agents that have activity in pancreatic adenocarcinoma and colorectal carcinoma. A potential association between germline mutations in DNA mismatch repair genes and ACC warrants further evaluation.
BACKGROUND:Acinar cell carcinoma (ACC) of the pancreas is a rare neoplasm, accounting for 1% of all pancreatic neoplasms. There remains a lack of data regarding the use of systemic therapy in this disease. We present a series of 40 consecutive cases of ACC of the pancreas treated at Memorial Sloan-Kettering Cancer Center, with an emphasis on evaluation of activity of new therapeutic agents. METHODS:Patients reviewed at our institution from January 2000 through January 2011 were identified from an institutional database with prior institutional review board approval. Pathology was confirmed in all cases as ACC or a closely related entity. RESULTS: Forty patients were identified; 29 were male (73%). The median age at diagnosis was 65 years (range, 16-87 years). The median overall survival (OS) time for patients with localized, resectable disease was 56.9 months and the OS time for patients with metastatic ACC (n = 18) was 19.6 months. Six patients with metastatic or recurrent ACC had a partial response to chemotherapy and five patients had stable disease for ≥6 months on systemic chemotherapy. Clinical observation was made of a patient with ACC and hereditary nonpolyposis colorectal cancer and a patient with ACC and a BRCA1 germline mutation. CONCLUSIONS: ACC is moderately chemoresponsive to agents that have activity in pancreatic adenocarcinoma and colorectal carcinoma. A potential association between germline mutations in DNA mismatch repair genes and ACC warrants further evaluation.
Authors: Kyle D Holen; David S Klimstra; Amanda Hummer; Mithat Gonen; Kevin Conlon; Murray Brennan; Leonard B Saltz Journal: J Clin Oncol Date: 2002-12-15 Impact factor: 44.544
Authors: Thierry Conroy; Françoise Desseigne; Marc Ychou; Olivier Bouché; Rosine Guimbaud; Yves Bécouarn; Antoine Adenis; Jean-Luc Raoul; Sophie Gourgou-Bourgade; Christelle de la Fouchardière; Jaafar Bennouna; Jean-Baptiste Bachet; Faiza Khemissa-Akouz; Denis Péré-Vergé; Catherine Delbaldo; Eric Assenat; Bruno Chauffert; Pierre Michel; Christine Montoto-Grillot; Michel Ducreux Journal: N Engl J Med Date: 2011-05-12 Impact factor: 91.245
Authors: Dhanpat Jain; Fatima Eslami-Varzaneh; Angela M Takano; Uma Ayer; Renuka Umashankar; Richard Muller; David S Klimstra Journal: Am J Surg Pathol Date: 2005-11 Impact factor: 6.394
Authors: Susan C Abraham; Tsung-Teh Wu; Ralph H Hruban; Jae-Hyuk Lee; Charles J Yeo; Kevin Conlon; Murray Brennan; John L Cameron; David S Klimstra Journal: Am J Pathol Date: 2002-03 Impact factor: 4.307
Authors: Emmet J Jordan; Olca Basturk; Jinru Shia; David S Klimstra; William Alago; Michael I D'Angelica; Ghassan K Abou-Alfa; Eileen M O'Reilly; Maeve A Lowery Journal: J Gastrointest Oncol Date: 2017-10
Authors: Alexander N Shoushtari; Anne M Covey; Ghazi Zaatari; Ali Shamseddine; Andrew S Epstein; Ali Haydar; Mohamed Naghy; Deborah Mukherji; David P Kelsen; Ghassan K Abou-Alfa; Eileen M O'Reilly Journal: Gastrointest Cancer Res Date: 2014-01
Authors: Vanessa L Gordon-Dseagu; Susan S Devesa; Michael Goggins; Rachael Stolzenberg-Solomon Journal: Int J Epidemiol Date: 2018-04-01 Impact factor: 7.196
Authors: Sebastian Zundler; Deike Strobel; Bernhard Manger; Markus F Neurath; Dane Wildner Journal: Curr Rheumatol Rep Date: 2017-08-26 Impact factor: 4.592
Authors: Frank Bergmann; Sebastian Aulmann; Bence Sipos; Matthias Kloor; Anja von Heydebreck; Johannes Schweipert; Andreas Harjung; Philipp Mayer; Werner Hartwig; Gerhard Moldenhauer; David Capper; Gerhard Dyckhoff; Kolja Freier; Esther Herpel; Anja Schleider; Peter Schirmacher; Gunhild Mechtersheimer; Günter Klöppel; Hendrik Bläker Journal: Virchows Arch Date: 2014-10-09 Impact factor: 4.064
Authors: Courtney J Pokrzywa; Daniel E Abbott; Kristina A Matkowskyj; Sean M Ronnekleiv-Kelly; Emily R Winslow; Sharon M Weber; Alexander V Fisher Journal: J Gastrointest Surg Date: 2019-01-31 Impact factor: 3.452
Authors: Stephan Kruger; Michael Haas; Philipp Johannes Burger; Steffen Ormanns; Dominik Paul Modest; Christoph Benedikt Westphalen; Axel Kleespies; Martin Kurt Angele; Werner Hartwig; Christiane Josephine Bruns; Thomas Kirchner; Jens Werner; Volker Heinemann; Stefan Boeck Journal: J Cancer Res Clin Oncol Date: 2016-09-14 Impact factor: 4.553
Authors: Yuchen Jiao; Raluca Yonescu; G Johan A Offerhaus; David S Klimstra; Anirban Maitra; James R Eshleman; James G Herman; Weijie Poh; Lorraine Pelosof; Christopher L Wolfgang; Bert Vogelstein; Kenneth W Kinzler; Ralph H Hruban; Nickolas Papadopoulos; Laura D Wood Journal: J Pathol Date: 2014-03 Impact factor: 7.996